Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Filings indexed 788 across all filing types
Latest filing 2014-09-08 Regulatory Filings
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce unscheduled material events or corporate changes. The content describes a press release about the first patient dosed in a Phase 1 study, which is an event announcement rather than a detailed financial report or earnings release. The document length is short (2317 characters), and it references a press release filed as an exhibit rather than containing substantive financial data or detailed management discussion. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2014-09-08 English
Director's Dealing 2014
Director's Dealing
2014-08-15 English
Director's Dealing 2014
Director's Dealing
2014-08-15 English
Director's Dealing 2014
Director's Dealing
2014-08-15 English
Director's Dealing 2014
Director's Dealing
2014-08-15 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions that the company issued a press release reporting financial and operational results for the second quarter of 2014, and that the press release is filed as an exhibit. The document itself does not contain the financial results but references the press release. The length of the document is short (2336 characters), and it primarily serves as an announcement of the earnings release rather than the earnings release itself. According to the rules, initial announcements of quarterly financial results are classified as Earnings Release (ER). Since this is a Form 8-K announcing the earnings release, and the actual financial data is in the press release exhibit, the best fit is Earnings Release (ER).
2014-08-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.